Secondary Care - Continuous Glucose Monitoring

Diabetes Mellitus, Type 2 Clinical Trial

— SC-COSMO  

Official title:

Continuous Glucose Monitoring in Patients With Diabetes Mellitus Type 2 in Secondary Care

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03487887
• Other study ID #: Program CGM u bolesnika T2DM
• Status: Completed
• Start date: March 19, 2018
• Est. completion date: August 25, 2021

Study information

• Verified date: August 2021
• Source: Croatian Society for Endocrinology and Diabology
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Introduction and objective: The current state of glucose monitoring includes the use of A1C, self-monitoring of blood glucose (SMBG), and continuous glucose monitoring (CGM). CGM technology has got the potential to revolutionize diabetes care in the near future striving to optimal diabetes management and tight glucose control. Until very recently, this determination could only be achieved by the attainment of multiple capillary blood glucose determinations each day and/or measuring hemoglobin A1C. Those methods are not accurate in cases of unrecognized hypoglycemia, unrecognized nighttime events or in cases of large swings in blood glucose. Our aim is to analyze the benefit of tracking patterns of glucose values by using professional CGM technology used for "blinded" collection of glucose data retrospectively in patients with T2DM in secondary care- diabetologist clinic.

Description:

STUDY DESIGN: An observational, multicenter, cross-sectional study. A total of 20 diabetologist from four Croatian regions will recruit up to ten subjects of both sexes from May 2018 till the end of May 2019, diagnosed with type 2 diabetes mellitus at least one year prior to study entry, aged ≥40 years, with only basal insulin in therapy and with clinical suspicion of hypoglycemia or with disproportion in actual glycaemia and hemoglobin A1c findings. Sociodemographic, laboratory (HbA1c, fasting and postprandial glucose, total cholesterol, and high density cholesterol, and low density cholesterol, triglyceride and serum creatinine) and habits data will be collected.

SETTING: Totally 100 of patients will be included. At diabetologist office each patient wear the device (iPro™2 Medtronic) subcutaneously for up to 7-days and return it to the office for download. Patients only see the CGM data after it's been analyzed by the healthcare professional. A CGM device is to be set and take off by the diabetologist. Before the study start all diabetologist who are not familiar to the method will have a short education. Study period is seven days and includes screening before study entry and two visits. On Day 1, after screening and signing the informed consent, the CGM device is applied. Patient is instructed to keep a 7 day diary with four daily standard SMBG along with the data on eating, physical exercise, drugs. On Day 7, CGM device is taken off and the data from iPro2 is uploaded to PC. At the end, each patient fills a short query on satisfaction while wearing CGM.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: August 25, 2021
• Est. primary completion date: August 25, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Days to 8 Days

Eligibility

Inclusion Criteria:

• T2DM diagnosed at least one year prior to study entry

• Only basal insulin in therapy

• Patients' ability to understand and answer the questionnaire by themselves

• Signed informed consent

Exclusion Criteria:

• Known coagulopathy

• Oral anticoagulants in therapy

• Skin disease that enables continuous glucose monitor device application

• Febrile illness

• Patient's inability to physically visit a general practitioners office

• Patient's inability to answer the questionnaire by themselves

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2

Intervention

Device:
• continuous glucose monitoring (CGM) iPro™2 Medtronic
A CGM device is to be set and take off by the diabetologist. Before the study start all diabetologist not familiar to the method will have a short education on CGM device. Study period is seven days and includes screening before study entry and two visits. On Day 1, after screening and signing the informed consent, the CGM device is applied. Patient is instructed to keep a 7 day diary with four daily standard SMBG along with the data on eating, physical exercise, drugs. On Day 7, CGM device is taken off and the data from iPro2 is uploaded to PC. At the end, each patient fills a short query on satisfaction while wearing CGM.

Locations

Country	Name	City	State
Croatia	University Hospital Centre Zagreb	Zagreb

Sponsors (2)

Lead Sponsor	Collaborator
Croatian Society for Endocrinology and Diabology	Takeda

Country where clinical trial is conducted

Croatia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Glycemic variability	Glycemic variability measured by continuous glucose monitor devicein individuals with type 2 diabetes mellitus in secondary care	7 days
Secondary	Hypogliaemia	Hypogliaemia measured by continuous glucose monitor device in individuals with type 2 diabetes mellitus in secondary care	7 days